[Seoul/December 31, 2019] – MD Healthcare Inc. today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square.
B&D Specialist Andrea McDowell will be presenting MD Healthcare Inc.’s core technology and assets at Biotech Showcase as follows:
Date: Tuesday, January 14, 2020
Time: 11:15 (PST)
Room: Franciscan B (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
MD Healthcare Inc. will present its innovative therapeutic and non-invasive diagnostic assets developed through its microbiome big data platform MD NanoBiome™. The company's drug pipelines have indications in immuno-oncology (MDH-001, MDH-203), inflammatory bowel disease (IBD) (MDH-001, MDH-301), obesity and Non-Alcoholic SteatoHepatitis (NASH) (MDH-301, MDH-902), respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) (MDH-101, MDH-201) as well as atopic dermatitis and depression (MDH-002). Furthermore, MD Healthcare will introduce its early diagnostic capabilities based on patient-derived big data and AI analytics using urine and blood samples.
“MD Healthcare Inc. is thrilled to present our company’s innovative microbiome extracellular vesicle convergence technology at Biotech Showcase 2020,” said Yoon-Keun Kim MD, PhD, CEO of MD Healthcare Inc. “We look forward to introducing our pre-clinical therapeutic and diagnostic assets to a wide audience of global industry leaders to facilitate strategic partnership, licensing, and investment opportunities.”
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that MD Healthcare Inc. will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT MD HEALTHCARE INC.
Founded in 2014 by Yoon-Keun Kim MD, PhD in South Korea, MD Healthcare Inc. is developing diagnostic and therapeutic solutions to intractable chronic diseases by harnessing microbiome metagenomic big data and AI technology. MD Healthcare’s proprietary microbial extracellular vesicle platform technology is accelerating the advancement of microbiome-based drug discovery and non-invasive In Vitro Diagnostics (IVD). MD Healthcare is staged to complete development of early diagnosis medical device software using big data-driven AI technology and proceed with the appropriate regulatory processes in 2020. Furthermore, MD Healthcare is expected to complete nonclinical efficacy evaluation for several of its drug pipelines in addition to GLP toxicity assessment in 2020 for clinical stage entry.
Contacts
For more information on partnering or investment opportunities with MD Healthcare Inc., please contact Andrea McDowell (email: ejan@mdhc.kr, phone: +82-70-7812-8071).
Visit MD Healthcare’s homepage www.mdhc.kr for more information on its microbiome-based therapeutic and diagnostic pipelines and follow Biotech Showcase at @EBDGroup and @Demy_Colton on twitter for further updates.
